Understanding a severe form of lung transplant rejection
Official title: Pathogenesis of Restrictive Allograft Syndrome Post-Lung Transplantation
Funded at Emory University · NIH-10749064 · Data updated 2026-11-12
This study is looking into restrictive allograft syndrome (RAS), a serious issue that can happen after lung transplants, to understand how certain immune cells and antibodies cause rejection, with the hope of finding better treatments to help lung transplant patients live longer and healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | December 8, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $595,755 |
| NIH project number | 5R01HL162171-04 |
| Project ID | NIH-10749064 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have undergone lung transplantation and are at risk for or experiencing restrictive allograft syndrome.
✕Less likely to help
Patients who have not received a lung transplant or those with other forms of transplant rejection unrelated to RAS may not benefit from this research.
What this research studies
This research investigates restrictive allograft syndrome (RAS), a serious condition that can occur after lung transplantation, leading to poor patient outcomes. The study aims to uncover the mechanisms behind RAS by examining the role of specific immune cells and antibodies in the rejection process. Using a mouse model that mimics human RAS, researchers will analyze how activated B cells and other immune components contribute to this aggressive form of rejection. The findings could help identify new therapeutic strategies to improve survival rates for lung transplant recipients.
Why it matters
Potential benefit: If successful, this research could lead to better treatments for patients experiencing severe lung transplant rejection, potentially improving their survival rates.
How similar studies have gone: Previous research has shown promising results in understanding immune responses in transplant rejection, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Lama, Vibha N — Emory University
- Study coordinator: Lama, Vibha N
Related research
Other NIH-funded projects on the same topics.
-
Body composition and outcomes after lung transplant
A patient-focused look at how body fat and muscle measurements around the time of lung transplant relate to recovery, complications, and quality of life after surgery.
-
Objective lung-donor quality tools to expand the transplant pool
A lung-transplant-focused project aims to use gene-based risk tools to better judge donor organs and prevent recipient lung dysfunction.
-
Bmp-Cx40 signaling to keep lung blood vessels calm after transplant
A study aims to keep blood vessels in transplanted lungs stable by boosting a specific signaling pathway to reduce injury after transplant.
-
Complement inhibition to protect transplanted lungs from early injury
A small early trial tests whether a drug that blocks a key part of the immune system can prevent damage to new lungs right after transplant.
-
Phase 1 trial of siltuximab for antibody-mediated rejection after lung transplant
A early-stage study tests whether siltuximab can help people who have antibody-mediated rejection after lung transplantation.
-
Targeted delivery of immune-suppressing agents to the lung graft to prevent rejection
A study at Northwestern University will test a new, targeted approach to prevent lung transplant rejection by delivering immune-suppressing drugs directly to the graft while blocking early signals that trigger rejection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.